Abstract
e12522 Background: High-grade glial tumors (HGGT) are aggressive tumors. We evaluate the prognostic importance of M65, M30, TNFα, CD105, VEGF, IL6, which are markers of inflammation, apoptosis, and angiogenesis, in HGGTs. Methods: Postoperative pretreatment serums were collected from 44 newly diagnosed HGGT patients. Control group (n=44) consisted of healthy people. Serum M30, M65, CD 105, VEGF, IL6 and TNFα levels were evaluated. Results: Median age of 44 patients with GBM (n=38, %86.3) and anaplastic glioma (n=6, %13.) was 59 (range: 30-80). Thirty-one patients were diagnosed with gross total excision, 10 with subtotal excision and 3 with stereotactic biopsy. Temozolomide concurrent with RT was performed in 37 patients. RT alone was performed in 6 patients. One patient did not receive RT because of poor performance status. Thereafter 24 patients received consolidation temozolomide monotherapy. In 37 patients, proggression free survival (PFS) and overall survival (OS) were 6 (%95 CI; 5.16-6.83) and 16 months (%95 CI; 13.07-18.93) respectively. CD105 (p=0.000) and TNFα (p=0.000) levels were statistically lower, however VEGF (p=0.030) levels were higher in patient group. Statistically insignificant low IL6 levels and high plasma apoptotic markers as M65 (p=0.085) ve M30 (p=0.292) levels were detected. In multiple regression analysis, biological markers did not show significance in survival (0.05<p). Conclusions: In HGGTs, low TNFα and IL6 levels with reduced proinflammatory activity and immunity, besides increased apoptotic activity and VEGF related angiogenesis were detected. Serum levels of markers. Markers N Mean Range P M30 (U/L) Patient Control 44 43 153.43 110.06 57.60-1006.27 57.60-259.05 0.292 M65(U/L) Patient Control 44 43 417.87 298.71 195.31-1590.51 191.64-600.40 0.850 IL6 (pg/mL) Patient Control 44 44 7.23 7.56 0.50-27.71 0.33-29.33 0.957 TNFα (pg/mL) Patient Control 44 44 14.01 45.57 0.60-87.24 0.95-93.05 0.000 VEGF (pg/mL) Patient Control 44 44 626.73 380.49 99.76-5200.53 72.76-1584.12 0.030 CD 105 (ng/mL) Patient Control 44 44 5.51 9.98 0.35-21.23 2.00-23.71 0.000
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
